Orgasm suppression + Dextropropoxyphene
Dextropropoxyphene is known to produce orgasm suppression, a physical effect. Orgasm suppression (anorgasmia) is the difficulty or complete inability to achieve orgasm despite adequate sexual stimulation, commonly caused by opioids, dissociatives, SSRIs, and stimulants through mechanisms including tactile suppression, serotonergic excess, and altered CNS signaling.
About Orgasm suppression
Orgasm suppression, clinically termed anorgasmia, describes a state in which achieving orgasm becomes markedly more difficult, requires much more intense or prolonged stimulation than normal, or becomes entirely impossible despite adequate arousal and stimulation. This is distinct from decreased libido (reduced desire) and erectile dysfunction (inability to achieve erection) — orgasm suppression can occur even when desire and physical arousal are intact, creating a particularly frustrating experience of being "almost there" but unable to reach climax.
The pharmacological mechanisms behind substance-induced anorgasmia are well-characterized. Serotonergic excess is the most common mechanism — elevated serotonin, particularly at 5-HT2A and 5-HT2C receptors, has a well-documented inhibitory effect on the orgasm reflex, which is why sexual dysfunction is the most commonly cited reason patients discontinue SSRIs.Opioids suppress orgasm through mu-receptor-mediated dampening of the spinal orgasmic reflex arc and through general CNS depression.Dissociatives produce anorgasmia primarily through their tactile-suppressing effects — when sensation from the genitals is diminished or disconnected from conscious perception, the sensory input necessary to trigger orgasm is insufficient.Stimulants can produce orgasm suppression through sympathetic nervous system overactivation and vasoconstriction, even while potentially increasing libido.
SSRI-induced anorgasmia deserves special mention due to its prevalence and clinical significance. Between 40-70% of patients on SSRIs report some degree of sexual dysfunction, with orgasm difficulty being the most common complaint. This has led to a variety of management strategies in psychiatric practice, including dose reduction, drug holidays (missing one or two doses before planned sexual activity — though this carries risks with certain SSRIs), switching to bupropion or mirtazapine (which have lower rates of sexual side effects), or adding buspirone or bupropion as adjuncts.
For recreational substance users, orgasm suppression is typically temporary and resolves with the substance's effects. However, the combination of enhanced intimacy, desire, and tactile pleasure with inability to climax — common with MDMA and opioids — can be either frustrating or, reframed, an opportunity to focus on the sensual experience itself rather than goal-oriented sexual activity.